- Home
- TRVI vs TSHA Comparison
TRVI vs TSHA Comparison
Compare TRVI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | TSHA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRVI | TSHA |
|---|---|---|
| Price | $12.79 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $20.38 | $10.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $8,333,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.24 | $1.13 |
| 52 Week High | $14.39 | $6.02 |
Technical Indicators
Market Signals| Indicator | TRVI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 46.72 |
| Support Level | $9.80 | $4.41 |
| Resistance Level | $14.39 | $5.16 |
| Average True Range (ATR) | 0.65 | 0.22 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 95.28 | 23.81 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.